When Patty Norman first noticed concerns about her memory, she and her husband, Tommy Norman, faced uncertainty about what ...

Restoring nicotinamide adenine dinucleotide (NAD+) homeostasis led to a pharmacologic reversal of advanced Alzheimer's ...

Alzheimer's disease affects the brain in tragic and seemingly irreversible ways, but a new study gives hope that its ...

Shanghai Fosun Pharmaceutical Group Co. will acquire a controlling stake in a Chinese company that developed the country’s ...

Two new groundbreaking drugs could slow the memory impairment, thinking skills and overall brain decline — and both are ...

Anytime older Americans see some good news about Alzheimer’s disease, you can bet they want to know all the details. Now, ...

US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...

A breakthrough new Alzheimer’s disease treatment is stopping neurodegeneration in its tracks, even before symptoms appear.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

The biopharmaceutical company accepted for filing a supplemental new drug application for AXS-05 to treat Alzheimer's disease agitation, and has granted the application priority review designation, ...

Axsome Therapeutics (AXSM) stock gains as the FDA grants priority review to expand its depression drug Auvelity for Alzheimer ...

Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.